<DOC>
	<DOCNO>NCT01276236</DOCNO>
	<brief_summary>The purpose study determine whether Maraviroc effective treatment Kaposi 's Sarcoma ( KS ) , remit standard antiretroviral drug therapy .</brief_summary>
	<brief_title>Effects Maraviroc ( MVC ) HIV-related Kaposi 's Sarcoma ( KS )</brief_title>
	<detailed_description>Although advent antiretroviral therapy ( ART ) may greatly decrease incidence Kaposi 's Sarcoma ( KS ) resource rich setting , KS continue prevalent AIDS-defining malignancy world carry significant morbidity mortality [ 1 ] . Indeed , recent epidemiological study examine cancer Kampala , Uganda , KS find second prostate cancer term incidence rate [ 2 ] . There grow evidence CCR5 may involve pathogenesis KS . Kaposi 's Sarcoma-associated Herpes Virus ( KSHV ) , agent find necessary KS pathogenesis [ 10 , 11 ] , encode viral macrophage inflammatory protein vMIP [ 7-9 ] . vMIP-I vMIP-II found ligands chemokine receptor , particular CCR5 receptor [ 5 , 6 ] , suggest potential role inflammatory process need KS pathogenesis . Further , vMIP-I induces Ca ( 2+ ) mobilization monocytes express CCR5 , suggest agonistic relationship vMIP-I CCR5 receptor [ 4 ] . In addition , vMIP find proangiogenic express endothelial cell , key feature KS tumor survival [ 12 ] . As well , CCR5 find significantly increase T cell population KS patient ( preliminary study ) , 2 double-blind , placebo-controlled phase 3 study total 1049 patient receive randomly assign drug MVC , trend reveal low incidence KS MVC arm v placebo ( 0.36 % vs 1.43 % ) [ 3 ] . This agonistic binding relationship protein vMIP CCR5 , proangiogenic activity associate vMIP , increased expression CCR5 KS , trend towards low incidence KS patient take MVC , suggest CCR5 may play important role KS pathogenesis . This involvement CCR5 KS pathogenesis implies MVC may function potential therapeutic KS . To date , study examine effect MVC KS . There need therapeutic development KS . Standard care KS involve initiation optimization antiretroviral therapy . A significant proportion KS case respond ART alone , non-response rate range 25-55 % , response time average 9 month depend patient series identify [ 13 , 14 ] . In severe case KS unresponsive ART , standard care involve systemic chemotherapy liposomal doxorubicin [ 15 ] , without adverse reaction . Adverse reaction liposomal doxorubicin include cardiac toxicity , nausea , vomit , diarrhea , abdominal pain , fatigue , patient may require pre-regime test vary cost , along resource time need intravenous infusion [ 16 ] . Nonresponse rate liposomal doxorubicin hover around 20 % [ 15 , 17 ] . Focal case may amenable radiation therapy intralesional velban [ 18 , 19 ] . However , radiation intralesional therapy limit focal site , require monitored visit specialize care , give limited amount , carry various adverse effect [ 18 , 19 ] . With nonresponse rate , potential adverse reaction , resource time need therapeutic delivery , clear benefit proferred effective oral therapy require minimal monitoring , case MVC . Maraviroc ( MVC ) member new class antiretroviral compound know small molecule CCR5 antagonists block R5 HIV entry CD4 cell . Maraviroc demonstrate selective reversible binding CCR5 , well potent antiviral activity vitro wide range laboratory adapt strain R5 HIV Clades A , B , C , D , E , F , G , J O. Maraviroc also retain vitro antiviral activity clinical isolates resistant exist drug class , activity virus enter CD4+ cell use CXCR4 . In vitro study approve antiretroviral medication indicate evidence antagonism member four class antiretroviral medication ; nucleoside/nucleotide reverse transcriptase inhibitor ( NRTIs ) , non- nucleoside reverse transcriptase inhibitor ( NNRTIs ) , protease inhibitor ( PIs ) fusion inhibitor . Although grow evidence CCR5 , potential therapeutic target , involved KS pathogenesis [ 3-9 ] , date study examine effect CCR5 inhibitor Maraviroc ( MVC ) KS . As , aim study examine effect Maraviroc , CCR5 inhibitor , KS .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>HIV1 infect , document licensed ELISA test kit confirm Western blot time prior study entry . HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test . Active biopsy confirm KS Screening plasma HIV RNA &lt; 75 copies/mL Patients unremitting KS . Unremitting define active biopsy confirm KS spite sustain HIV RNA &lt; 75 copies/mL 24 prior month . Isolated value detectable &lt; 500 copy allow long plasma HIV RNA level time point undetectable . &gt; 90 % adherence therapy within precede 30 day , determine selfreport . Both male female subject eligible . Females childbearing potential must negative serum pregnancy test screen agree use doublebarrier method contraception throughout study period . Ability willingness subject legal guardian/representative provide inform consent Patients intend modify antiretroviral therapy next 24 week reason . Serious illness require hospitalization parental antibiotic within precede 3 month . Concurrent treatment immunomodulatory drug therapy , exposure immunomodulatory drug therapy past 16 week . Prior exposure CCR5 inhibitor Screening absolute neutrophil count &lt; 1,000 cells/mm3 , platelet count &lt; 50,000 cells/mm3 , hemoglobin &lt; 8mg/dL , estimate creatinine clearance &lt; 40 mL/minute . Elevated transaminase great 2.5 time upper limit normal . Evidence cirrhosis Pregnant breastfeed woman Use Tenofovir Didanosine current antiretroviral therapy regimen . Local therapy KS index lesion precede 60 day , unless lesion clearly progress enlargement since local therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Kaposi 's Sarcoma</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>CCR5</keyword>
	<keyword>HIV</keyword>
</DOC>